IXLAYER TAKES “HEALTHCARE TECHNOLOGY INNOVATION OF THE YEAR” IN THE 2025 STEVIE AWARDS FOR TECHNOLOGY EXCELLENCE
ixlayer’s DTP Platform, ixEngage, Accelerates Care and Earns Top Honors for its Patient-First End-to-End Technology for BioPharma
SAN FRANCISCO, CA/August 11, 2025 – ixlayer, an award-winning provider of cloud-based platforms powering direct-to-patient healthcare, has been named the winner of a Silver Stevie® Award in the Healthcare Innovation of the Year category as part of the Stevie Awards for Technology Excellence. This award recognizes the remarkable achievement ixlayer has made in shaping the future of technology in healthcare. This is the sixth industry award ixlayer has won in 2025.
ixlayer captured the award for ixEngage, its direct-to-patient platform purpose-built for biopharma. The white-label solution seamlessly integrates remote testing, national diagnostic-lab networks, independent telehealth providers, and pharmacies—engineering personalized diagnostic journeys that strip away friction and expand access to care. As a result, pharma brands using ixEngage are reaching a far wider pool of eligible patients than traditional in-office models.
“Our mission is to remove barriers to care, so patients get the tests and treatments they need—without delays, PTO days or missed appointments,” said Pouria Sanae, co-founder and CEO of ixlayer. “This Silver Stevie Award is yet another testament to the advanced engineering acumen of our team and the trust our biopharma partners place in us to help them modernize patients’ healthcare experience.”
More than 1,500 nominations from organizations of all sizes in 36 nations and territories were submitted this year for consideration across tech-related categories. More than 160 professionals worldwide participated in the judging process to select this year’s honorees.
Details about the Stevie Awards for Technology Excellence and the list of 2025 Stevie winners are available at www.StevieAwards.com/Tech.
About ixlayer
ixlayer [pronounced: I-X-layer] is an award-winning provider of cloud-based platforms that power a seamless, end-to-end direct-to-patient healthcare experience. The name reflects our core strength: “i” for robust data and technology infrastructure and “x” for exceptional user experience. ixlayer offers ixEngage–a proprietary solution for biopharma that seamlessly integrates with all healthcare ecosystem partners from at-home sample collection kits to labs and at-home prescription delivery, ixlayer’s patient-centric technology accelerates the path to diagnosis, supports optimal care, drives operational efficiency, and improves health equity and outcomes for all. To date, ixlayer has activated over four million patient care journeys, simplifying the complex web of a patient’s healthcare journey. Learn more at www.ixlayer.com.
About the Stevie Awards
Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Great Employers, the Stevie Awards for Women in Business, the Stevie Awards for Technology Excellence and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations and territories. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performance in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.
MEDIA CONTACTS:
Jennifer Perciballi
Oak+Cannon for ixlayer
jennifer@oakandcannon.com
CLICK HERE to learn more about how ixlayer works with biopharma leaders to integrate a complete end-to-end, direct-to-patient experience into their marketing campaigns.
About ixlayer
ixlayer has the only end-to-end, direct-to-patient platform built for biopharma and optimized for patient choice. We help biopharma companies connect with patients from testing to treatment with speed, transparency, control and impact.
